Russell Investments Group Ltd. decreased its position in shares of Biohaven Ltd. (NYSE:BHVN – Free Report) by 4.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 27,686 shares of the company’s stock after selling 1,382 shares during the quarter. Russell Investments Group Ltd.’s holdings in Biohaven were worth $378,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also made changes to their positions in BHVN. US Bancorp DE grew its stake in shares of Biohaven by 19.1% during the 1st quarter. US Bancorp DE now owns 586 shares of the company’s stock worth $70,000 after purchasing an additional 94 shares during the period. Cetera Advisor Networks LLC purchased a new position in shares of Biohaven during the 1st quarter valued at approximately $332,000. AlphaCrest Capital Management LLC purchased a new position in shares of Biohaven during the 1st quarter valued at approximately $344,000. BlackRock Inc. lifted its position in shares of Biohaven by 0.5% during the 1st quarter. BlackRock Inc. now owns 4,656,866 shares of the company’s stock valued at $552,163,000 after buying an additional 21,586 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of Biohaven by 55.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 82,599 shares of the company’s stock valued at $9,794,000 after buying an additional 29,413 shares in the last quarter. Institutional investors and hedge funds own 89.60% of the company’s stock.
Biohaven Stock Performance
Shares of BHVN stock opened at $18.94 on Monday. The stock’s fifty day moving average is $21.66 and its two-hundred day moving average is $17.93. The firm has a market capitalization of $1.29 billion, a P/E ratio of -2.55 and a beta of 1.12. Biohaven Ltd. has a fifty-two week low of $5.54 and a fifty-two week high of $26.64.
Analysts Set New Price Targets
BHVN has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. decreased their target price on Biohaven from $27.00 to $24.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 16th. BTIG Research increased their target price on Biohaven from $24.00 to $28.00 in a research report on Monday, June 5th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, Biohaven presently has a consensus rating of “Buy” and an average target price of $25.25.
Insider Buying and Selling at Biohaven
In related news, Director John W. Childs acquired 100,000 shares of the firm’s stock in a transaction dated Friday, August 4th. The stock was acquired at an average price of $19.78 per share, for a total transaction of $1,978,000.00. Following the purchase, the director now owns 1,925,118 shares of the company’s stock, valued at approximately $38,078,834.04. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other news, Director John W. Childs acquired 100,000 shares of Biohaven stock in a transaction on Friday, August 4th. The stock was bought at an average price of $19.78 per share, for a total transaction of $1,978,000.00. Following the completion of the purchase, the director now owns 1,925,118 shares in the company, valued at $38,078,834.04. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director John W. Childs bought 50,000 shares of the company’s stock in a transaction dated Wednesday, August 30th. The stock was bought at an average cost of $18.44 per share, for a total transaction of $922,000.00. Following the acquisition, the director now owns 1,975,118 shares of the company’s stock, valued at approximately $36,421,175.92. The disclosure for this purchase can be found here. 12.40% of the stock is currently owned by corporate insiders.
Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; BHV-7010, a Kv7 channel modulator for the treatment of different neurological diseases; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat, an oral myeloperoxidase inhibitor, which is in Phase 3 clinical trial for the treatment of neurodegenerative diseases.
- Five stocks we like better than Biohaven
- How to Invest in Social Media
- MarketBeat Week in Review – 8/28 – 9/1
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- 2 Stocks That Doubled EPS Estimates and Flashing Buy Signals
- Roth IRA Calculator: Calculate Your Potential Returns
- Toyota vs Tesla: The Tortoise And The Hare Race Has A New Meaning
Receive News & Ratings for Biohaven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven and related companies with MarketBeat.com's FREE daily email newsletter.